Top

Current Heart Failure Reports

Published in:

01-10-2020 | Dyspnea | Ethics/Palliative Care (S Fedson, Section Editor)

Home Therapies in Advanced Heart Failure: Inotropes and Diuretics

Authors: Jason P. Graffagnino, Leslie C. Avant, Bethany C. Calkins, Keith M. Swetz

Published in: Current Heart Failure Reports | Issue 5/2020

Abstract

Purpose of Review

Heart failure (HF) is a significant cause of morbidity, mortality, and decreased quality of life (QOL). Symptoms, including reduced activity tolerance, fatigue, palpitations, and dyspnea, result from volume overload or low output states. Herein, we review the best available literature supporting diuretic and inotropic therapies in advanced HF and how these improve QOL.

Recent Findings

While diuretics and inotropes reduce symptoms and hospitalizations in advanced HF, there is an increased risk of harms with both modalities. While diuretic complications include electrolyte and renal function abnormalities, adverse event data with inotropes is more complex and includes possible arrhythmias and death. Further, inotrope utilization is complicated by required intravenous access, infusion costs, and limited outpatient support.

Summary

Ambulatory use of diuretics and inotropes may improve patients’ QOL through symptom management and reduced hospitalizations. However, risks and limitations of both modalities must be considered as treatment decisions are made.

Virani SS, Alonso A, Benjamin EJ, Bittencort MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics--2020 update. A report from the American Heart Association. Circulation. 2020;141(9):e136–596. https://doi.org/10.1161/CIR.0000000000000757.CrossRef

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. https://doi.org/10.1016/j.jacc.2013.05.019.CrossRefPubMed

Verbrugge FH, Tang WHW, Mullens W. Renin-angiotensin-aldosterone system activation during decongestion in acute heart failure. Friend or foe? JACC Heart Fail. 2015;3(2):108–11. https://doi.org/10.1016/j.jchf.2014.10.005.CrossRefPubMed

Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341(8):577–85. https://doi.org/10.1056/NEJM199908193410806.CrossRefPubMed

Blecker S, Herrin J, Li L, Yu H, Grady JN, Horwitz LI. Trends in hospital readmission of Medicare-covered patients with heart failure. J Am Coll Cardiol. 2019;73(9):1004–12. https://doi.org/10.1016/j.jacc.2018.12.040.CrossRefPubMedPubMedCentral

Lin AH, Chin JC, Sicignano NM, Evans AM. Repeat hospitalizations predict mortality in patients with heart failure. Mil Med. 2017;182(9):e1932–7. https://doi.org/10.7205/MILMED-D-17-00017.CrossRefPubMed

Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73(2):257–67. https://doi.org/10.1161/01.cir.73.2.257.CrossRefPubMed

Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000;36(5):1587–93. https://doi.org/10.1016/s0735-1097(00)00912-8.CrossRefPubMed

Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation. 2013;127(4):500–7; discussion 508. https://doi.org/10.1161/CIRCULATIONAHA.112.120485.CrossRefPubMed

10.

Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10):1987–96. https://doi.org/10.1016/j.jacc.2005.11.084.CrossRefPubMed

11.

Abraham J, Bharmi R, Jonsson O, Oliveria GH, Artia A, Valika A, et al. Association of ambulatory hemodynamic monitoring of heart failure with clinical outcomes in a concurrent matched cohort analysis. JAMA Cardiol. 2019;4(6):556–63. https://doi.org/10.1001/jamacardio.2019.1384.CrossRefPubMedPubMedCentral

12.

Ellison DH. Clinical pharmacology in diuretic use. Clin J Am Soc Nephrol. 2019;14(8):1248–57. https://doi.org/10.2215/CJN.09630818.CrossRefPubMedPubMedCentral

13.

Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387–95. https://doi.org/10.1056/nejm199808063390607.CrossRefPubMed

14.

Oh SW, Han SY. Loop diuretics in clinical practice. Electrolyte Blood Press. 2015;13(1):17–21. https://doi.org/10.5049/ebp.2015.13.1.17.CrossRefPubMedPubMedCentral

15.

Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96(3–4):132–43. https://doi.org/10.1159/000047397.CrossRefPubMed

16.

Asare K. Management of loop diuretic resistance in the intensive care unit. Am J Health Syst Pharm. 2009;66(18):1635–40. https://doi.org/10.2146/ajhp090068.CrossRefPubMed

17.

Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int. 1982;22(1):69–74. https://doi.org/10.1038/ki.1982.134.CrossRefPubMed

18.

Brater DC. Pharmacology of diuretics. Am J Med Sci. 2000;319(1):38–50. https://doi.org/10.1097/00000441-200001000-00004.CrossRefPubMed

19.

Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57(6):601–9. https://doi.org/10.1016/0009-9236(95)90222-8.CrossRefPubMed

20.

Bailie GR, Grennan A, Waldek S. Bioavailability of bumetanide in grossly oedematous patients. Clin Pharmacokinet. 1987;12(6):440–3. https://doi.org/10.2165/00003088-198712060-00004.CrossRefPubMed

21.

Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985;102(3):314–8. https://doi.org/10.7326/0003-4819-102-3-314.CrossRefPubMed

22.

Gehr TW, Rudy DW, Matzke GR, Kramer WG, Sica DA, Brater DC. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther. 1994;56(1):31–8. https://doi.org/10.1038/clpt.1994.98.CrossRefPubMed

23.

Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, et al. Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF trial). Am J Cardiol. 2016;117(3):404–11. https://doi.org/10.1016/j.amjcard.2015.10.059.CrossRefPubMed

24.

Rahhal A, Saad MO, Tawengi K, Assi AAR, Habra M, Ahmed D. Torsemide versus furosemide after acute decompensated heart failure: a retrospective observational study. BMC Cardiovasc Disord. 2019;19(1):127. https://doi.org/10.1186/s12872-019-1112-5.CrossRefPubMedPubMedCentral

25.

•• Abraham B, Megaly M, Sous M, Fransawyalkomos M, Saad M, Fraser R, et al. Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure. Am J Cardiol. 2020;125(1):92–9. https://doi.org/10.1016/j.jamjcard.2019.09.039. Torsemide was associated with a statistically significant improvement in functional class and lower risk of cardiac mortality in patients with worse NYHA functional class (III/IV) compared with those with better functional class (I/II).CrossRefPubMed

26.

Miles JA, Hanumanthu BK, Patel K, Chen M, Siegel RM, Kokkinidis DG. Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis. J Cardiovasc Med (Hagerstown). 2019;20(6):379–88. https://doi.org/10.2459/JCM.0000000000000794.CrossRef

27.

Rao VS, Planavsky N, Hanberg JS, Ahmad T, Brisco-Bacik MA, Wilson FP, et al. Compensatory distal reabsorption drives diuretic resistance in human heart failure. J Am Soc Nephrol. 2017;28(11):3414–24. https://doi.org/10.1681/ASN.2016111178.CrossRefPubMedPubMedCentral

28.

Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 1989;36(4):682–9. https://doi.org/10.1038/ki.1989.246.CrossRefPubMed

29.

Almeshari K, Ahlstrom NG, Capraro FE, Wilcox CS. A volume-independent component to postdiuretic sodium retention in humans. J Am Soc Nephrol. 1993;3(12):1878–83.PubMed

30.

• Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. JACC Heart Fail. 2020;8(3):157–68. https://doi.org/10.1016/j.jchf.2019.09.012The addition of metolazone, chlorothiazide, or tolvaptan to loop diuretics aided in diuresis and urine output, but not a statistically significant different.CrossRefPubMed

31.

Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse B, Ellison DH. Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(−)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol. 2001;12(7):1335–41.PubMed

32.

Pitt B, Remme W, Zannad F, Nealton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21. https://doi.org/10.1056/NEJMoa030207.CrossRefPubMed

33.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17. https://doi.org/10.1056/NEJM199909023411001.CrossRefPubMed

34.

Zannad F, McMurray JJV, Krum H, van Veldhusin DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. https://doi.org/10.1056/NEJMoa030207.CrossRefPubMed

35.

List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–7. https://doi.org/10.2337/dc08-1863.CrossRefPubMed

36.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.CrossRefPubMed

37.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. https://doi.org/10.1056/NEJMoa1811744.CrossRefPubMed

38.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389.CrossRefPubMed

39.

• McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa191103Patients receiving dapagliflozin over placebo experienced lower risk of worsening HF or death from cardiovascular causes regardless of whether the patient was diabetic or not.CrossRefPubMed

40.

Anderson SL. Dapagliflozin efficacy and safety: a perspective review. Ther Adv Drug Saf. 2014;5(6):242–54. https://doi.org/10.1177/2042098614551938.CrossRefPubMedPubMedCentral

41.

Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764–9. https://doi.org/10.7326/M19-0085.CrossRefPubMed

42.

Heyward J, Mansour O, Olson L, Singh S, Alexander GC. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis. PLoS One. 2020;15(6):e0234065. https://doi.org/10.1371/journal.pone.0234065.CrossRefPubMedPubMedCentral

43.

• Makadia S, Simmons T, Augustine S, et al. The diuresis clinic: a new paradigm for the treatment of mild decompensated heart failure. Am J Med. 2015;128:527–31. https://doi.org/10.1016/j.amjmed.2014.11.028Treatment of mild HF decompensations in an outpatient parenteral diuretic clinic resulted in a “cost-effective decline” in rehospitalization rates.CrossRefPubMed

44.

Greene SJ, Wilson LE, Abbasi SA, Yusuf AA, Hammill BG. Outpatient intravenous diuretic therapy for heart failure in the United States. J Am Coll Cardiol. 2019;73(9):1101–3. https://doi.org/10.1016/j.jacc.2018.12.034.CrossRefPubMedPubMedCentral

45.

Ryder M, Murphy NF, McCaffrey D, O’Loughlin C, Ledwidge M, McDonald K. Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. Eur J Heart Fail. 2008;10(3):267–72. https://doi.org/10.1016/j.ejheart.2008.01.003.CrossRefPubMed

46.

•• Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805. https://doi.org/10.1056/NEJMoa1005419No improvement in global symptom burden or change in renal function when parenteral loop diuretics were administered either by intermittent bolus over continuous infusion or by high dose compared with low dose.CrossRefPubMedPubMedCentral

47.

Sica DA, Muntendam P, Myers RL, Ter Maaten JM, Sale ME, de Boer RA, et al. Subcutaneous furosemide in heart failure: pharmacokinetic characteristics of a newly buffered solution. JACC Basic Transl Sci. 2018;3(1):25–34. https://doi.org/10.1016/j.jacbts.2017.10.001.CrossRefPubMedPubMedCentral

48.

Gilotra NA, Princewill O, Marino B, Okwuosa IS, Chasler J, Almansa J, et al. Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Fail. 2018;6(1):65–70. https://doi.org/10.1016/j.jchf.2017.10.001.CrossRefPubMed

49.

Jozwiak R, Marks S. Subcutaneous diuretics for end-of-life management of heart failure #353. J Palliat Med. 2018;21(6):879–80. https://doi.org/10.1089/jpm.2018.0199.CrossRefPubMed

50.

Afari ME, Aoun J, Khare S, Tsao L. Subcutaneous furosemide for the treatment of heart failure: a state-of-the art review. Heart Fail Rev. 2019;24(3):309–13. https://doi.org/10.1007/s10741-018-9760-6.CrossRefPubMed

51.

• Abraham WT, Adams KF, Fonarow GC, Costanza MR, Berkowitz RL, LeJemtel TH, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46(1):57–64. https://doi.org/10.1016/j.jacc.2005.03.051Positive inotropic therapy was associated with a significantly higher in-hospital mortality for patient with acute decompensated HF versus those who received vasodilator or natriuretic peptide treatments.CrossRefPubMed

52.

Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(12):1541–7. https://doi.org/10.1001/jama.287.12.1541.CrossRefPubMed

53.

Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005;96(6A):47g–58g. https://doi.org/10.1016/j.amjcard.2005.07.021.CrossRefPubMed

54.

Rossinen J, Harjola VP, Siirila-Waris K, Lassus J, Melin J, Peuhkurinen K, et al. The use of more than one inotrope in acute heart failure is associated with increased mortality: a multi-centre observational study. Acute Card Care. 2008;10(4):209–13. https://doi.org/10.1080/17482940802262376.CrossRefPubMed

55.

Khush KK, Cherikh WS, Chambers DC, Goldfarb S, Hayes D Jr, Kucheryavaya AY, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult heart transplantation report-2018; focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018;37(10):1155–68. https://doi.org/10.1016/j.healun.2018.07.022.CrossRefPubMed

56.

Gosev I, Kiernan MS, Eckman P, Soleimani B, Kilic A, Uriel N, et al. Long-term survival in patients receiving a continuous-flow left ventricular assist device. Ann Thorac Surg. 2018;105(3):696–701. https://doi.org/10.1016/j.athoracsur.2017.08.057.CrossRefPubMed

57.

• Hashim T, Sanam K, Revilla-Martinez M, Morgan CJ, Tallaj JA, Pamboukian SV, et al. Clinical characteristics and Outcomes of intravenous inotropic therapy in advanced heart failure. Circ Heart Fail. 2015;8(5):880–6. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001778Median survival for patients with AHF who are not candidates for transplantation or LVAD who receive palliative inotropic therapy remains low at 9 months; 1-year survival 47.6%, 2-year survival 38.4%.CrossRefPubMed

58.

Hershberger RE, Nauman D, Walker TL, Dutton D, Burgess D. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail. 2003;9(3):180–7. https://doi.org/10.1054/jcaf.2003.24.CrossRefPubMed

59.

Guglin M, Kaufman M. Inotropes do not increase mortality in advanced heart failure. Int J Gen Med. 2014;7:237–51. https://doi.org/10.2147/IJGM.S62549.CrossRefPubMedPubMedCentral

60.

Vallet B, Dupuis B, Chopin C. Dobutamine: mechanisms of action and use in acute cardiovascular pathology (French). Ann Cardiol Angeiol (Paris). 1991;40(6):397–402.

61.

Puddu PE, Papalia U, Schiariti M, Usta C. Dobutamine effects on spontaneous variability of ventricular arrhythmias in patients with severe chronic heart failure: the Italian multicenter study. Ital Heart J. 2004;5(9):693–701.PubMed

62.

Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis. 1995;38(2):167–80. https://doi.org/10.1016/s0033-0620(05)80005-2.CrossRefPubMed

63.

• Martens P, Vercammen J, Ceyssens W, Jacobs L, Luwel E, Van Aerde H, et al. Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure. ESC Heart Fail. 2018;5(4):562–9. https://doi.org/10.1002/ehf2.12248Small study demonstrating home intravenous dobutamine improved symptom severity, HF hospitalizations, and healthcare-related costs.CrossRefPubMedPubMedCentral

64.

Scholz H, Dieterich HA, Schmitz W. Mechanism of the positive inotropic effect of phosphodiesterase inhibitors (German). Z Kardiol. 1991;80 Suppl 4:1–6.PubMed

65.

Cesario D, Clark J, Maisel A. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J. 1998;135(1):121–9. https://doi.org/10.1016/S0002-8703(98)70352-7.CrossRefPubMed

66.

Hatzizacharias A, Makris T, Krespi P, Triposkiadis F, Voyatzi P, Dalianis N, et al. Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure. Am Heart J. 1999;138(2 Pt 1):241–6. https://doi.org/10.1016/s0002-8703(99)70107-9.CrossRefPubMed

67.

Loh E, Elkayam U, Cody R, Bristow M, Jaski B, Colucci WS. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail. 2001;7(2):114–21. https://doi.org/10.1054/jcaf.2001.24136.CrossRefPubMed

68.

Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. the PROMISE Study Research Group. N Engl J Med. 1991;325(21):1468–75. https://doi.org/10.1056/NEJM199111213252103.CrossRefPubMed

69.

DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989;320(11):677–83. https://doi.org/10.1056/NEJM198903163201101.CrossRefPubMed

70.

Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006;113(2):305–15. https://doi.org/10.1161/CIRCULATIONAHA.105.542407.CrossRefPubMed

71.

Nanayakkava S, Byrne M, Mak V, Carter K, Dean E, Kaye DM. Extended-release oral milrinone for the treatment of heart failure with preserved ejection fraction. J Am Heart Assoc. 2020;9:e015026. https://doi.org/10.1161/JAHA.119.015026.CrossRef

72.

Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1(2):103–11. https://doi.org/10.1016/j.jchf.2012.12.004.CrossRefPubMed

73.

Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297(17):1883–91. https://doi.org/10.1001/jama.297.17.1883.CrossRefPubMed

74.

Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J. 2002;66(2):149–57. https://doi.org/10.1253/circj.66.149.

75.

Lubsen J, Just H, Hjalmarsson AC, la Framboise D, Remme WJ, Heinrich-Nols J, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart. 1996;76(3):223–31. https://doi.org/10.1136/hrt.76.3.223.CrossRefPubMedPubMedCentral

76.

Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use. J Cardiovasc Pharmacol. 2020;7(1):4–22. https://doi.org/10.1097/FJC.0000000000000859.CrossRef

77.

Harjola V-P, Giannakoulas G, von Lewinski D, Matskeplishvili S, Mebazaa A, Papp Z, et al. Use of levosimendan in acute heart failure. Eur Heart J Suppl. 2018;20(Suppl I):I2–I10. https://doi.org/10.1093/eurheartj/suy039.CrossRefPubMedPubMedCentral

78.

Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med. 1988;318(6):358–65. https://doi.org/10.1056/NEJM198802113180606.CrossRefPubMed

79.

Patel N, Ju C, Macon C, Thadani U, Schulte PJ, Hernandez AF, et al. Temporal trends of digoxin use in patients hospitalized with heart failure: analysis from the American Heart Association Get With The Guidelines-Heart Failure Registry. JACC Heart Fail. 2016;4(5):348–56. https://doi.org/10.1016/j.jchf.2015.12.003.CrossRefPubMed

80.

Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JGF, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15(5):551–9. https://doi.org/10.1093/eurjhf/hft010.CrossRefPubMedPubMedCentral

81.

Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullall AJ, Than CT, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660–8. https://doi.org/10.1016/j.jacc.2014.03.060.CrossRefPubMedPubMedCentral

82.

Chong LYZ, Satya K, Kim B, Berkowitz R. Milrinone dosing and a culture of caution in clinical practice. Cardiol Rev. 2018;26(1):35–42. https://doi.org/10.1097/CRD.0000000000000165.CrossRefPubMed

83.

Groninger H, Gilhuly D, Walker KA. Getting to the heart of the matter: a regional survey of current hospice practices caring for patients with heart failure receiving advanced therapies. Am J Hosp Palliat Care. 2019;36(1):55–9. https://doi.org/10.1177/1049909118789338.CrossRefPubMed

Title: Home Therapies in Advanced Heart Failure: Inotropes and Diuretics
Authors: Jason P. Graffagnino
Leslie C. Avant
Bethany C. Calkins
Keith M. Swetz
Publication date: 01-10-2020
Publisher: Springer US
Keywords: Dyspnea
Diuretics
Heart Failure
Dyspnea
Furosemide
Milrinone
Published in: Current Heart Failure Reports / Issue 5/2020
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-020-00482-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 5/2020

Big Data Approaches in Heart Failure Research

Heart Failure–Induced Skeletal Muscle Wasting

Cardiovascular Magnetic Resonance for the Differentiation of Left Ventricular Hypertrophy

Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension: Ready for Clinical Practice and Guidelines?

The Role of TGF—β Signaling in Cardiomyocyte Proliferation

Central Sleep Apnea in Patients with Heart Failure—How to Screen, How to Treat

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage